L-Citrulline

L-Citrulline

SCHEMBL16098618

CC(O)CC(=O)O.NC(=O)NCCC[C@H](N)C(=O)O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ OTC P00480 1/20 0.47
▸ DDAH1 O94760 3/20 0.44
▸ BHMT Q93088 1/20 0.42
▸ NOS2 P35228 7/20 0.41
▸ NOS1 P29475 6/20 0.41
▸ NOS3 P29474 4/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ GSR P00390 1/20 0.40
▸ GLA P06280 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Citrulline SCHEMBL16098617 1.00 OTC (0.47) OTCDDAH1BHMTNOS2NOS1
Arginine SCHEMBL16099880 0.88 OTC (0.44) OTCDDAH1BHMTNOS2NOS1
Arginine SCHEMBL16099882 0.88 OTC (0.44) OTCDDAH1BHMTNOS2NOS1
Arginine SCHEMBL19459580 0.88 OTC (0.44) OTCDDAH1BHMTNOS2NOS1
L-Citrulline SCHEMBL9056465 0.87 OTC (0.51) OTCDDAH1NOS2NOS1NOS3
L-Citrulline SCHEMBL31412725 0.87 OTC (0.51) OTCDDAH1NOS2NOS1NOS3
L-Citrulline SCHEMBL9056462 0.87 OTC (0.51) OTCDDAH1NOS2NOS1NOS3
L-Citrulline SCHEMBL27996119 0.87 OTC (0.51) OTCDDAH1NOS2NOS1NOS3
L-Citrulline SCHEMBL319675 0.86 OTC (0.48) OTCDDAH1NOS2NOS1NOS3
L-Citrulline SCHEMBL31672873 0.86 OTC (0.48) OTCDDAH1NOS2NOS1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806328-B2 Metabolic therapy for wound healing UNIVERSITY OF SOUTH FLORIDA (US) 2023-11-07 — — US claimed
US-20210093602-A1 METABOLIC THERAPY FOR WOUND HEALING UNIVERSITY OF SOUTH FLORIDA 2021-04-01 — — US claimed
US-10864184-B1 Metabolic therapy for wound healing UNIVERSITY OF SOUTH FLORIDA (US) 2020-12-15 — — US claimed
US-20200268701-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIV SOUTH FLORIDA (US) 2020-08-27 — — US claimed
US-10646462-B2 Compositions and methods for producing elevated and sustained ketosis UNIVERSITY OF SOUTH FLORIDA (US) 2020-05-12 — — US claimed
WO-2019200132-A1 COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET Metabolic Recovery Systems, LLC (US) 2019-10-17 — — WO claimed
US-20190313682-A1 COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET Metabolic Recovery Systems, LLC 2019-10-17 — — US claimed
EP-2976073-B1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIV SOUTH FLORIDA (US) 2019-08-28 — — EP claimed
US-20180021281-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS SCIADONICS, INC. 2018-01-25 — — US claimed
WO-2018017667-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS SCIADONICS, INC. (US) 2018-01-25 — — WO claimed
US-20170266148-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2017-09-21 — — US claimed
US-9675577-B2 Compositions and methods for producing elevated and sustained ketosis UNIVERSITY OF SOUTH FLORIDA (US) 2017-06-13 — — US claimed
US-20160067207-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2016-03-10 — — US claimed
EP-2976073-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS University Of South Florida (US) 2016-01-27 — — EP claimed
US-9138420-B2 Compositions and methods for producing elevated and sustained ketosis UNIVERSITY OF SOUTH FLORIDA (US) 2015-09-22 — — US claimed
US-20140350105-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-11-27 — — US claimed
WO-2014153416-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-09-25 — — WO claimed
US-20240226043-A1 ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS AXCESS GLOBAL SCIENCES, LLC 2024-07-11 — — US disclosed
US-20140350105-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-11-27 — — US disclosed
WO-2014153416-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021281-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS FAAH, ELOVL1, DGKA OTC 4557/4885DDAH1 641/4885BHMT 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback